C-CAR168 clinical trials
C-CAR168 is named as an intervention in 3 current clinical trials in our USA and China registers. 1 is recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is AbelZeta Inc (2). The most-studied condition is Multiple Sclerosis.
Patient leaflets for C-CAR168
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of C-CAR168
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NCT06249438 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD)
|
Phase 1 | Recruiting | RenJi Hospital | China |
|
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
NCT07825389 · ClinicalTrials.gov ↗ · Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS)
|
Phase 1/2 | Not yet open | AbelZeta Inc | USA |
|
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
NCT07854483 · ClinicalTrials.gov ↗ · Systemic Sclerosis (SSc), Systemic Sclerosis, Systemic Sclerosis (Scleroderma)
|
Phase 1 | Not yet open | AbelZeta Inc | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with C-CAR168
12 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbelZeta Inc | 2 |
| RenJi Hospital | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 0 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about C-CAR168 trials
How many clinical trials are testing C-CAR168?
3 current trials in our USA and China registers name C-CAR168 (also registered as CD20/BCMA-directed CAR-T cells) as a drug or biological intervention, as of the registry sync on 14 October 2026. Completed and withdrawn studies are not counted.
Are C-CAR168 trials recruiting patients?
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors C-CAR168 clinical trials?
AbelZeta Inc (2) and RenJi Hospital (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how C-CAR168 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how C-CAR168 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists C-CAR168 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 14 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.